Cellular Health Screening Global Market Report 2024

The cellular health screening market has grown rapidly in recent years. It will grow from $3.01 billion in 2023 to $3.37 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%.The expansion observed in the historical period can be ascribed to the growing awareness of health, a demographic shift towards an aging population, prevailing trends in preventive healthcare, an upsurge in chronic diseases, and advancements in biomarker research.

The cellular health screening market is expected to see rapid growth in the next few years. It will grow to $5.04 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth in the forecast period can be credited to a heightened emphasis on personalized medicine, the implementation of corporate wellness programs, government initiatives promoting preventive healthcare, and the escalating prevalence of lifestyle-related health issues. Key trends expected in the forecast period involve the application of AI and machine learning, a surge in consumer awareness, integration with wearable devices, collaborative efforts in research and development, and the support of regulatory frameworks and standardization.

The increasing prevalence of chronic diseases is poised to drive the growth of the cellular health screening market in the foreseeable future. Chronic diseases, characterized by prolonged durations and requiring ongoing management, can be effectively managed through cellular health screening. This diagnostic approach aids in early detection of chronic diseases, considering factors such as genetic predisposition, lifestyle choices, environmental conditions, and underlying health issues. For instance, data from October 2022 by the Centers for Disease Control and Prevention indicates that coronary heart disease, affecting approximately 20.1 million individuals aged 20 and older, is the most common type of heart disease in the United States. The rise in chronic diseases is a significant factor propelling the expansion of the cellular health screening market.

The growth of the cellular health screening market is anticipated to be fueled by the increasing aging population. As demographics shift towards a higher proportion of elderly individuals globally, cellular health screening becomes crucial for assessing cellular function, potential health risks, and personalized preventive measures in the aging population. According to projections from October 2022 by the World Health Organization, by 2030, one in six individuals worldwide will be aged 60 or older. This demographic shift is expected to result in a rise from 1 billion to 1.4 billion in the population aged 60 and over by 2030. By 2050, the global population aged 60 and older is estimated to double, reaching 2.1 billion. The aging population is a key driver for the growth of the cellular health screening market.

Leading companies in the cellular health screening market are focusing on innovation to enhance their offerings, exemplified by initiatives such as lung cancer screening through routine blood tests. Lung cancer screening, a critical aspect of cellular health assessment, is facilitated by companies such as DELFI Diagnostics, Inc. In October 2023, DELFI Diagnostics launched 'FirstLook Lung,' a blood test providing precise and personalized outcomes for detecting lung cancer using low-dose CT (LDCT). With a negative predictive value (NPV) of 99.7 percent, this innovative solution aids in identifying optimal courses of action for subsequent screening stages, benefitting both patients and healthcare providers.

Companies at the forefront of the cellular health screening market are leveraging artificial intelligence (AI) to develop advanced solutions, such as AI-based Non-Small Cell Lung Cancer (NSCLC) molecular panels. Imagene AI, a notable player in the industry, introduced 'LungOI' in September 2023, representing the world's first AI-based NSCLC molecular panel. This diagnostic tool employs AI technology to analyze genetic and molecular information associated with NSCLC, providing healthcare professionals with immediate genomic insights from biopsy images alone. The AI-based NSCLC molecular panel offers a groundbreaking approach to cancer diagnosis and treatment decisions.

In August 2021, Illumina Inc., a prominent biotechnology company, completed the acquisition of Grail Inc. for an undisclosed amount. This strategic move positioned Illumina to enter the cancer screening market and bolster its capabilities in genomics and precision medicine. Grail Inc., known for its focus on developing blood tests for early cancer detection, played a pivotal role in enhancing Illumina's presence and offerings in the cellular health screening market.

Major companies operating in the cellular health screening market report are Bio-Reference Laboratories Inc., Laboratory Corporation, Quest Diagnostics Incorporated, Cell Science Systems, Genova Diagnostics, Immundiagnostik AG, Life Length, Repeat Diagnostics Inc., Segterra Inc., SpectraCell Laboratories Inc., Telomere Diagnostics Inc., Zimetry LLC, Cleveland HeartLab Inc., Agilent Technologies Inc., DNA Labs India, Bloom Diagnostics GmbH, True Health Diagnostics LLC, Vibrant America LLC, CellMax Life, BioAge Labs Inc., InsideTracker Inc., BioMark Laboratories, BioTelemetry Inc., Biophysical Corporation, Boston Heart Diagnostics Corporation, Cenegenics LLC, Cyrex Laboratories LLC, Diagnostic Solutions Laboratory, Epigenomics AG, Genalyte Inc., Genomind Inc., Health Diagnostic Laboratory Inc., InCellDx Inc., Interleukin Genetics Inc., MDxHealth SA, Myriad Genetics Inc., Natera Inc., Pathway Genomics Corporation.

North America was the largest region in the cellular health screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global cellular health screening market report during the forecast period. The regions covered in the cellular health screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cellular health screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of tests for cellular health screening include single-test panels, telomere tests, oxidative stress tests, inflammation tests, heavy metals tests, and multi-test panels. Single-test panels are diagnostic assessments that target specific aspects of an individual's health, often concentrating on a particular biomarker or physiological function. These tests involve various sample types, such as blood, saliva, serum, and urine, with the flexibility of collection at multiple sites, including homes, offices, hospitals, and diagnostic labs.

The cellular health screening market research report provides cellular health screening market statistics, including cellular health screening industry global market size, regional shares, competitors with a cellular health screening market share, detailed cellular health screening market segments, market trends and opportunities, and any further data you may need to thrive in the cellular health screening industry. This cellular health screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cellular health screening market includes revenues earned by entities by assessing inflammatory conditions, such as allergies, asthma, arthritis, and autoimmune conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.